Cart summary

You have no items in your shopping cart.

Paritaprevir

SKU: orb1305953

Description

Paritaprevir (ABT450) is a potent small molecule inhibitor targeting the HCV NS3/4A serine protease. It demonstrates high antiviral activity with EC50 values of 1 nM against HCV genotype 1a and 0.21 nM against genotype 1b. This compound is a key research tool for studying HCV replication and antiviral mechanisms in biochemical and cellular assays.

Research Area

Infectious Disease & Virology, Protein Biochemistry

Images & Validation

Key Properties

CAS Number1216941-48-8
MW765.88
Purity99.72% (May vary between batches)
FormulaC40H43N7O7S
SMILESCc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1
TargetSARS-CoV,HCV Protease
SolubilityDMSO:80 mg/mL (104.46 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (4.31 mM)

Bioactivity

Target IC50
HCV NS3/4A 4a:0.09 nM|HCV NS3/4A 6a:0.69nM|HCV NS3/4A 1a:1.0 nM|HCV NS3/4A 2a:5.3 nM|HCV 1a:1 nM(EC50)|HCV NS3/4A 3a:19 nM|HCV NS3/4A 1b:0.21 nM|HCV 1b:0.21 nM(EC50)
In Vivo
Paritaprevir/ritonavir/ombitasvir with dasabuvir (PrOD) is a novel combination of a nonstructural (NS) 3/4A protein inhibitor boosted by ritonavir, an NS5A protein inhibitor, and an NS5B nonnucleoside polymerase inhibitor. The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections1.

Storage & Handling

Storagekeep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Ritonavir, SARS coronavirus, SARS-CoV 3CLPpro, SARS-CoV, Veruprevir, 1221573-85-8, ABT450, ABT-450, ABT 450, CYP450, Inhibitor, HCV 1a, HCV 1b, HCV genotype 1a, HCV genotype 1b, HCV, HCVProtease, HCV Protease, HCV NS3/4A, Hepatitis C virus, inhibit, NS3/4A, Paritaprevir, orally active

Similar Products

  • Paritaprevir free base [orb1304404]

    99.26%

    1221573-85-8

    765.89

    C40H43N7O7S

    5 mg, 10 mg, 25 mg, 1 ml x 10 mM (in DMSO)
  • Paritaprevir dihydrate [orb1983374]

    1456607-71-8

    801.91

    C40H47N7O9S

    5 mg, 50 mg
  • Paritaprevir (b) [orb1226762]

    >98%(HPLC)

    1221573-85-8

    765.9

    C40H43N7O7S

    50 mg, 100 mg, 200 mg, 5 mg, 10 mg, 1 g, 500 mg, 25 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Paritaprevir (orb1305953)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
¥ 2,860.00
10 mg
¥ 4,160.00
1 ml x 10 mM (in DMSO)
¥ 5,200.00
25 mg
¥ 6,760.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry